By continuing to access the site you are agreeing to their use. Learn more about cookies. hamburger-icon INVESTORS FINANCIAL HIGHLIGHTS FINANCIAL HIGHLIGHTS Net revenue from continuing operations up 7% (+13% on an organic basis5) to £458.6m (2020: £428.6m). Adjusted EBITDA from continuing operations decreased by 10% (-5% on an organic basis5) to £116.3m, (2020: £129.8m) reflecting the impact of COVID-19 and a change in gross profit mix partially offset by good cost control. Adjusted EPS from continuing operations down 14% to 55.9p (2020: 65.3p). Net debt as at 30 June 2021 of £316.9m, (£335.8m inc. IFRS 16 liabilities7) representing net debt leverage of 2.8x8, meaningfully below the Group’s temporary banking covenant of 3.5x. Group expected to de-lever significantly over the course of this financial year to below 2.5x by the end of FY2022 and within our stated target of below 2.0x within FY2023. Strong cash conversion with adjusted operating cash flow for the year from continuing operations up 6% to £99.9m (2020: £93.9m). OUR TRACK RECORD Please click on the image to enlarge. RELATED LINKS ANNUAL REPORT ANNUAL REPORT 2021 Download report (pdf 4.64mb) INVESTORS INVESTMENT CASE Read more SHARE TOOLS SHARE TOOLS View all OUR GLOBAL OFFICES United Kingdom Europe Asia, Pacific and Japan South Africa United States SITE TOOLS Stay In Touch AE Reporting Medical enquiries Terms of use Cookies Privacy policy Privacy Statement for Pharmacovigilance Data UK Gender Pay Gap Report Modern Slavery Statement Access Online Sitemap Consumer Information Obligations Clinigen Terms And Conditions Of Business (Sales) Clinigen Terms And Conditions Of Business (Purchases) FIND A MEDICINE Online services for healthcare professionals Hard to find medicines (Clinigen Direct) Managed Access Programs (Cliniport) Clinigen Products Twitter Linkedin © Copyright 2021 Clinigen Group plc. By Emperor

By continuing to access the site you are agreeing to their use. Learn more about cookies. hamburger-icon INVESTORS INVESTOR CONTACTS INVESTOR RELATIONS Investor Relations Email: Investors@clinigengroup.com OUR GLOBAL OFFICES United Kingdom Europe Asia, Pacific and Japan South Africa United States SITE TOOLS Stay In Touch AE Reporting Medical enquiries Terms of use Cookies Privacy policy Privacy Statement for Pharmacovigilance Data UK Gender Pay Gap Report Modern Slavery Statement Access Online Sitemap Consumer Information Obligations Clinigen Terms And Conditions Of Business (Sales) Clinigen Terms And Conditions Of Business (Purchases) FIND A MEDICINE Online services for healthcare professionals Hard to find medicines (Clinigen Direct) Managed Access Programs (Cliniport) Clinigen Products Twitter Linkedin © Copyright 2021 Clinigen Group plc. By Emperor